Related StoriesStudy reveals mechanism behind protein-related diseasesResearchers successfully repair nerve cell harm in Alzheimer's dementiaRice researchers solve long-position mystery about hemophilia proteinAllena’s founders and other members of the Allena team have considerable encounter in the development of oral enzyme substitute and nonsystemic protein therapeutics, including oxalate-degrading enzymes. The certified hyperoxaluria portfolio from Althea also contains supportive Phase 1 scientific data in 58 healthy volunteers . There is significant value and opportunity in this hyperoxaluria portfolio and a real patient need for a highly effective treatment. We realize the Allena group and feel they are best outfitted to translate the potential of this portfolio and the previous clinical findings into a fresh and novel proteins therapy, said Magda Marquet, Ph.D., co-chairman and founder of Althea Technologies.Testbed in pc science department A few years back, anyone wandering around Jolley or Bryan halls, two structures occupied by the WUSTL Section of Computer Science on the Danforth Campus, may have noticed little green circuit boards the size of business cards poking out from between acoustic tiles in the ceiling. Occasionally, coloured LEDs on the boards would blink on / off as the researchers experimented with their testbed.